EGFR mutation status in a series of Turkish non-small cell lung cancer patients

Calibasi-Kocal, Gizem; Amirfallah, Arsalan; Sever, Tolga; Ünal, Olçun Ümit; Gürel, Duygu; Öztop, İlhan; Ellıdokuz, Hülya; Başbınar, Yasemin

doi:10.3892/br.2020.1308

Cited by 9 publications

(30 citation statements)

References 36 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Erlotinib therapy was associated with increased survival in these patients. 155 The overall frequency of all EGFR mutations in Turkish patients with NSCLC is estimated at over 16%, 156,157 with 32% and 20% of cases expressing exon 19 and 21 mutations, respectively. 158 Frequency estimates were significantly higher in female patients and non-smokers.…”

Section: Turkeymentioning

confidence: 99%

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

Dalurzo¹,

Avilés‐Salas²,

Soares³

et al. 2021

OTT

View full text Add to dashboard Cite

The treatment of patients with advanced non-small-cell lung cancer (NSCLC) in recent years has been increasingly guided by biomarker testing. Testing has centered on driver genetic alterations involving the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements. The presence of these mutations is predictive of response to targeted therapies such as EGFR tyrosine kinase inhibitors (TKIs) and ALK TKIs. However, there are substantial challenges for the implementation of biomarker testing, particularly in emerging countries. Understanding the barriers to testing in NSCLC will be key to improving molecular testing rates worldwide and patient outcomes as a result. In this article, we review EGFR mutations and ALK rearrangements as predictive biomarkers for NSCLC, discuss a selection of appropriate tests and review the literature with respect to the global uptake of EGFR and ALK testing. To help improve testing rates and unify procedures, we review our experiences with biomarker testing in China, South Korea, Russia, Turkey, Brazil, Argentina and Mexico, and propose a set of recommendations that pathologists from emerging countries can apply to assist with the diagnosis of NSCLC.

show abstract

Section: Turkeymentioning

confidence: 99%

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

Dalurzo¹,

Avilés‐Salas²,

Soares³

et al. 2021

OTT

View full text Add to dashboard Cite

show abstract

“…In 2020, lung cancer was still the leading cancer worldwide in terms of mortality. NSCLC accounts for nearly 85% of these cancers [1]. In the era of conventional cytotoxic drugs, the prognosis for this cancer was grim [2].…”

Section: Introductionmentioning

confidence: 99%

Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era

Refeno

Lamuraglia

Terrisse

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: The identification of activating mutations in specific genes led to the development of targeted therapies for NSCLC. TKI directed against EGFR-mutations were the first to prove their major efficacy. Medical associations recommend their use as first and second-line metastatic treatments in EGFR-mutated patients. Our objective was to analyze the survival of EGFR-mutated patients treated beyond the second line of treatment. Methods: We performed a longitudinal, retrospective and analytical study at APHP (Assistance Publique Hopitaux de Paris) Saint Louis, Paris, France, from 1 January 2010 to 31 December 2020 (11 years), on EGFR-mutated patients with metastatic NSCLC which received TKI or chemotherapy (CT) in third-line. Results: Out of about 107 EGFR-mutated patients, 31 patients who benefited from TKI or CT in the third line of treatment were retained for this study. The mean age was 60.03 ± 11.93 years and the sex ratio male/female was 0.24. Mutations of exon 19, 21 and 20 were found in 21 (67.7%), 7 (22.6%) and 7 (22.6%) patients, respectively. Third-line treatment was CT for 16 patients (51.6%) and TKI for the 15 remaining patients (48.4%). Osimertinib was the most used TKI in third-line (n = 10/15; 66.67%). The median duration of third-line treatment was 5.37 months (range 0.53–37.6) and the median follow-up duration was 40.83 months (range 11.33–88.57). There was a significant difference in PFS between patients treated with TKI and CT in third-line (p = 0.028). For patients treated with CT in second-line, there was a significant difference of PFS (p < 0.001) and OS (p = 0.014) in favor of the use of TKI in third-line. Conclusions: For patients receiving CT in second-line, TKI appears to be a better alternative in third-line compared to CT. Osimertinib may be used in third line treatment if not used before.

show abstract

“…Original articles were identi ed from Jordan [19], Iran [20,21], Turkey [22][23][24][25][26], Bahrain [27], Iraq [29,30], Lebanon [31][32][33], Morocco [35][36][37], Tunisia [38][39][40], Egypt [41], and Algeria [42]. A multicenter prospective study from Levant (Lebanone, Syria, Palestine, Jordan, Iraq, and Egypt) [34] and a multisite retrospective study from Gulf region (Saudi Arabia, the United Arab Emirates and Qatar) were also identi ed and will part of our analysis [28].…”

Section: Introductionmentioning

confidence: 99%

“…EGFR mutation analysis was carried out with quantitative PCR analysis in the study from Gulf region [41]. The INFINITI system using BioFilmChip-based microarray assay was used in one study from Turkey [22]. Details of the study methods and population characteristics are summarized in Table 1.…”

Section: Introductionmentioning

confidence: 99%

“…In the Levant and Gulf regions, EGFR mutations were found in 15.6% (32/205) [34] Concurrent mutations were found in 1.2% (14/1171) of the included patients. A total of 12 Turkish patients had multiple exon mutations [22,23,25]. A single Turkish study reported that 8 patients harbored concurrent mutations: 1 patient had mutations in exon 18 and exon 19, 3 patients had mutations in exon 18 and exon 21, 1 patient had mutations in exon 19 and exon 21, and 3 patients had mutations in exon 20 and exon 21 [22].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and Patterns of EGFR Mutations in Non-Small Cell Lung Cancer in the Middle East and North Africa: A Systematic Review

Boustany

Laraqui

Rhaffouli

et al. 2021

Preprint

View full text Add to dashboard Cite

To summarize current evidence and estimate the prevalence of epidermal growth factor receptor (EGFR) mutation frequency and its association with ethnicity and clinic-pathological features in non-small cell lung cancer (NSCLC) patients in the Middle East (ME) and North Africa (NA), a systematic literature review was undertaken. We conducted a literature search of original articles published in six databases (PubMed, Science Direct, Web of Science, Embase, Scopus, and Google scholar) from the time of inception until April 2021. Search terms included “lung cancer”, “NSCLC”, “EGFR mutation”, “Middle East”, “North Africa”, and specific country names belonging to the considered region. The included studies had to meet the following criteria: the study must relate to the role of the EGFR gene in NSCLC, analyze mutations in exon 18, 19, 20, and 21 or select exons of the EGFR gene, and provide sufficient information on the clinic-pathological characteristics of the included NSCLC patients. A total of 24 eligible studies were included [(66.6%) in the ME and (34.4%) in NA]. Overall, 6544 patients with NSCLC were analyzed for EGFR mutations [(55.1%) in the ME and (44.8%) in NA]. The overall prevalence of EGFR mutations was 17.9%. In the ME, the reported frequency was 17.3%, whereas in NA, the prevalence of EGFR mutations was 18.5%. The most frequently encountered mutations were the exon 19 deletions (45.2%) and exon 21 substitutions (30.9%). Exon 20 alterations were detected in 11.2%, of which, the T790M resistance mutation was the most prevalent (45.5%). Exon 18 mutations were reported in 3.8%. In the ME, 50.5% of NSCLC patients were positive for exon 19 deletions versus 48.3% in NA. Exon 21 mutations were slightly more commonly detected in the ME (36.3%) than NA (31.3%). There was 1.2% of patients that had concurrent EGFR mutations. Overall, EGFR mutations prevalence was higher in females, non-smokers, and patients with adenocarcinoma. Our systematic literature review concurs that EGFR mutation prevalence among MENA populations is slightly higher than that seen in NSCLC patients of Caucasian ethnicity but is lower than that identified in Asian NSCLC patients. The distribution of these mutations varies significantly throughout the MENA region.

show abstract

EGFR mutation status in a series of Turkish non-small cell lung cancer patients

Cited by 9 publications

References 36 publications

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era

Prevalence and Patterns of EGFR Mutations in Non-Small Cell Lung Cancer in the Middle East and North Africa: A Systematic Review

Contact Info

Product

Resources

About